Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: The effect of stopping or reducing the dose of vincristine in diffuse large B-cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R-CHOP treatment regimens with and without vincristine reduction in DLBCL patients.
Methods: This retrospective study was conducted on newly diagnosed DLBCL patients during 2018-2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R-CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared.
Results: Overall, 269 patients with DLBCL were included in this study, 15.99% of whom ( = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R-CHOP regimen ( > 0.05). Besides, no difference was observed in the 1-year overall survival (OS) and progression-free survival (PFS) of the patients in the two groups treated with R-CHOP regimen with and without vincristine reduction ( > 0.05). The complete remission rates of the patients treated with R-CHOP regimen with and without vincristine ( > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R-CHOP treatment regimen had no relationship with the 1-year OS and PFS of the DLBCL patients (hazard ratio [HR] = 1.59, 95% confidence interval [CI]: 3.67-0.690, HR = 1.67, 95% CI: 0.798-3.82).
Conclusion: The results of this study showed that the reduction of vincristine from the R-CHOP regimen in the DLBCL patients was not likely to make a difference in the 1-year OS and PFS of the patients. However, further studies are needed on the issue.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684988 | PMC |
| http://dx.doi.org/10.1002/hsr2.1716 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary bladder diffuse large B-cell lymphoma: A rare case report.
Int J Surg Case Rep
September 2025
Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Yunnan Province, China. Electronic address:
Introduction: Diffuse large B-cell lymphoma (DLBCL), a common subtype of non-Hodgkin lymphoma (NHL), originates primarily from lymph nodes, with a small proportion arising extranodally in sites such as the gastrointestinal tract and central nervous system. Given the general absence of lymphoid tissue in the bladder, primary bladder DLBCL is exceptionally rare.
Case Presentation: This case report describes an 83-year-old male patient with a bladder mass, initially suspected as cystitis glandularis, ultimately diagnosed via pathological examination as DLBCL.
Primary diffuse large B-cell lymphoma of non-germinal center type with BCL-6 positivity in the kidney: A case report.
Int J Surg Case Rep
August 2025
Department of Urology, The Fourth Affiliated Hospital of Dali University, Chuxiong, Yunnan 675000, China. Electronic address:
Introduction And Importance: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, yet primary renal involvement is rare, constituting less than 1 % of renal malignancies. A case of non-germinal center B-cell-like (non-GCB) DLBCL with BCL-6 positivity is particularly unique. Conventionally, BCL-6 is linked to germinal center B-cell-like (GCB) subtypes.
View Article and Find Full Text PDFAssessment of the efficacy and prognostic value of 18F-FDG PET-CT using deauville 5-point scale and ΔSUVmax methods in diffuse large B-cell lymphoma patients.
Medicine (Baltimore)
September 2025
Department of Nuclear Medicine, Xi'an Gaoshang Medical Imaging Diagnosis Center, Xi'an, Shaanxi, China.
Diffuse large B-cell lymphoma (DLBCL) requires accurate therapeutic response assessment. This study evaluates the efficacy and prognostic value of [18F] fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) using the Deauville 5-point scale and maximum standardized uptake value (ΔSUVmax) methods in DLBCL patients. A retrospective study was conducted from January 2021 to December 2022, including 60 DLBCL patients.
View Article and Find Full Text PDFUnusual Presentation of Primary Cardiac Lymphoma in a 61-Year-Old Woman: A Case Report.
Clin Case Rep
September 2025
Department of Radiation Oncology, School of Medicine, Shahid Rajayee Hospital Babol University of Medical Sciences Babol Iran.
Primary cardiac lymphoma (PCL) is one of the rarest primary malignancies of the heart. This report describes a rare presentation of diffuse large B-cell lymphoma (DLBCL) in a 61-year-old woman from Iran who presented with weakness, dyspnea, and bilateral lower extremity edema, especially on the right side that progressively worsened over 2 years. Initial diagnostic workup, including laboratory tests, color Doppler ultrasound, and echocardiography, revealed a large immobile mass attached to the RA wall.
View Article and Find Full Text PDFObinutuzumab-induced severe acute thrombocytopenia: a case report and literature review.
Front Immunol
September 2025
Department of Haematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Multiple clinical studies have shown that compared with rituximab combined with chemotherapy, obinutuzumab combined with chemotherapy can significantly improve the progression-free survival (PFS) of patients, effectively reduce the risk of disease progression, and improve patient prognosis. The main adverse effects of obinutuzumab include infusion reactions, myelosuppression, infection, cardiotoxicity, tumor lysis syndrome (TLS), etc.
View Article and Find Full Text PDF